APA

Hoskin P., Sartor O., O'Sullivan J. M., Johannessen D. C., Helle S. I., Logue J., Bottomley D., Nilsson S., Vogelzang N. J., Fang F., Wahba M., Aksnes A. & Parker C. (20150223). Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. : The Lancet. Oncology.

Chicago

Hoskin Peter, Sartor Oliver, O'Sullivan Joe M, Johannessen Dag Clement, Helle Svein I, Logue John, Bottomley David, Nilsson Sten, Vogelzang Nicholas J, Fang Fang, Wahba Mona, Aksnes Anne-Kirsti and Parker Christopher. 20150223. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. : The Lancet. Oncology.

Harvard

Hoskin P., Sartor O., O'Sullivan J. M., Johannessen D. C., Helle S. I., Logue J., Bottomley D., Nilsson S., Vogelzang N. J., Fang F., Wahba M., Aksnes A. and Parker C. (20150223). Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. : The Lancet. Oncology.

MLA

Hoskin Peter, Sartor Oliver, O'Sullivan Joe M, Johannessen Dag Clement, Helle Svein I, Logue John, Bottomley David, Nilsson Sten, Vogelzang Nicholas J, Fang Fang, Wahba Mona, Aksnes Anne-Kirsti and Parker Christopher. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. : The Lancet. Oncology. 20150223.